Evolent Health (EVH) Cost of Revenue (2015 - 2026)

Evolent Health's Cost of Revenue history runs 12 years deep, the most recent figure standing at $412.5 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 8.21% year-over-year to $412.5 million in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 25.84% decrease from a year earlier, with the FY2025 full-year figure at $1.5 billion, down 32.51% from the prior year.
• Cost of Revenue advanced to $412.5 million in Q1 2026 per EVH's latest filing, from $371.5 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $570.8 million in Q4 2024 and bottomed at $219.7 million in Q1 2022.
• The 5-year median for Cost of Revenue is $379.8 million (2025), against an average of $389.1 million.
• Across the five-year window, Cost of Revenue jumped 82.01% in 2022 and plunged 36.34% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $299.4 million in 2022, then soared by 51.8% to $454.4 million in 2023, then gained by 25.62% to $570.8 million in 2024, then slumped by 34.93% to $371.5 million in 2025, then increased by 11.04% to $412.5 million in 2026.
• Per Business Quant, the three latest EVH Cost of Revenue figures stand at $412.5 million (Q1 2026), $371.5 million (Q4 2025), and $379.8 million (Q3 2025).